Palmer 1982.

Methods	Allocation: randomised Blinding: double blind Design: parallel study Sample size at entry 20: auranofin 10; placebo 10 Analysis: Completers (50% followup)
Participants	Country: New Zealand Patients with active RA Age: mean 52.25 y Disease duration: not reported Females: 75% RF: not reported Concomitant use of steriods: Intra‐articular steroids allowed Concomitant use of DMARDs: none Previous use of DMARDS: none
Interventions	Auranofin 6 mg/day vs identical placebo Treatment duration: 6 mo.
Outcomes	Tender joints: Ritchie index Swollen joints Pain Patient's assessment score (4 pt scale, 0=nil, 3=excellent) Time to walk 5 M ESR
Notes	Quality score: 4 Allocation concealment: adequate Results estimated from graphs by two reviewers and averaged. No SDs reported. Withdrawals & ADRs reported at 2 yrs.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate